Bayer plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, with operations beginning in 2031. The company announced the project Friday in a joint press release with Ohio Governor Mike DeWine and JobsOhio.
The facility will create approximately 600 permanent jobs, plus roughly 1,500 construction jobs. The campus features a modular design integrating both drug substance and drug product manufacturing with advanced automation. The first module (drug substance) opens in 2031; the second module (drug product) follows in 2034.
Bayer CEO Bill Anderson said, "Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment. The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad."
For BAYRY investors, this matters. The facility supports Bayer's oncology, cardiovascular, and renal care portfolios—the company's growth engines in its largest market. It also hedges supply-chain risk and domestic capacity constraints, critical for pricing and margin defense as competitors race to lock in U.S. manufacturing. With first revenues seven years out, this is a long-dated catalyst, but it anchors the durability of the pharma franchise.
The new site will complement Bayer's existing U.S. pharmaceutical headquarters in Whippany, N.J. and operations in Pittsburgh, Berkeley, Cambridge, Research Triangle Park, and San Diego.
Bayer has invested more than $7 billion in U.S. pharmaceutical research, development, and manufacturing over the past five years. Ohio's workforce readiness was a draw—Bayer plans to use the Ohio Life Science Training Center, opening summer 2027, to train operators and technicians.
